Medication Competition Act

Hozzl · 2026-04-30T04:53:23Z

Explore the details of Senate Bill 4332 Medication Competition Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

4/30/2026, 4:53 AM

Summary of Bill S 4332

This bill, introduced in the 119th Congress as S.4332 on April 16, 2026, aims to mandate the Secretary of Health and Human Services to assess the exclusivity periods applicable to licensed biological products, specifying the eligibility criteria for such periods.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4332

Bill S 4332 is currently in the status of Bill Introduced since April 16, 2026. Bill S 4332 was introduced during Congress 119 and was introduced to the Senate on April 16, 2026. Bill S 4332's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 16, 2026

Bipartisan Support of Bill S 4332

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4332

Primary Policy Focus

Alternate Title(s) of Bill S 4332

A bill to require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible.

Comments

Sponsors and Cosponsors of S 4332

Margaret Wood Hassan

New HampshireDemocrat

Ted Budd

North CarolinaRepublican

Latest Bills

VAMOSA Act of 2025

Bill HR 6654May 11, 2026

CONNECT Act

Bill HR 7995May 11, 2026

To designate the facility of the United States Postal Service located at 201 East Grant Avenue in Georgetown, Ohio, as the "Ulysses S. Grant Post Office Building".

Bill HR 7809May 11, 2026